EP1906912A4 - Procede permettant de prolonger la vie d'animaux - Google Patents

Procede permettant de prolonger la vie d'animaux

Info

Publication number
EP1906912A4
EP1906912A4 EP06774663A EP06774663A EP1906912A4 EP 1906912 A4 EP1906912 A4 EP 1906912A4 EP 06774663 A EP06774663 A EP 06774663A EP 06774663 A EP06774663 A EP 06774663A EP 1906912 A4 EP1906912 A4 EP 1906912A4
Authority
EP
European Patent Office
Prior art keywords
ppm
animal
composition
vitamin
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06774663A
Other languages
German (de)
English (en)
Other versions
EP1906912A1 (fr
EP1906912B1 (fr
Inventor
Steven Curtis Zicker
Karen Joy Wedekind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hills Pet Nutrition Inc
Original Assignee
Hills Pet Nutrition Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hills Pet Nutrition Inc filed Critical Hills Pet Nutrition Inc
Publication of EP1906912A1 publication Critical patent/EP1906912A1/fr
Publication of EP1906912A4 publication Critical patent/EP1906912A4/fr
Application granted granted Critical
Publication of EP1906912B1 publication Critical patent/EP1906912B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the invention relates generally to methods for prolonging the life of animals and particularly to the use of antioxidants for prolonging the life of animals.
  • Free radical-induced oxidative stress is a major factor in the long-term tissue degradation associated with aging. Living cells during their normal functions continuously produce free radicals. Free radicals are highly reactive substances capable of reacting irreversibly with many biological molecules, thus causing progressive deterioration of the biological system that eventually results in aging and death. Free radicals are normally neutralized by the body's production of antioxidant enzymes and nutrient-derived antioxidants. Numerous studies have been conducted to determine whether antioxidants can reduce oxidative stress or affect the longevity of animals. While animals currently live longer and have a better quality of life due to improved nutrition and medical care, there is still a need for new or alternative methods and compositions for increasing the longevity of animals, in particular animals that are already old.
  • the present invention provides methods for increasing the longevity of an animal.
  • the methods comprise administering to the animal when the animal is old an antioxidant-comprising composition.
  • An antioxidant-comprising composition is a composition comprising one or more antioxidants, and optionally additional ingredients. The total antioxidant amount of the one or more antioxidants in the composition is sufficient to increase the longevity of the animal.
  • the antioxidant-comprising composition is a food composition that is administered by feeding the composition to the animal.
  • the invention provides an article of manufacture comprising (a) a package containing a composition that comprises one or more antioxidants in a total antioxidant amount sufficient, when administered to an old animal, to increase the longevity of the animal; and (b) a means for communicating information about or instructions for administering the composition to an old animal to increase the longevity of the animal, said communicating means being attached to or enclosed in the package.
  • the invention also provides a kit comprising (a) a first package containing a composition that comprises one or more antioxidants in a total antioxidant amount sufficient, when administered to an old animal, to increase the longevity of the animal; (b) a second package containing a food base; and (c) a means for communicating information about or instructions for adding the antioxidant-comprising composition to the food base and administering the resulting antioxidant-fortified composition to an old animal to increase the longevity of the animal.
  • a communicating means as provided in the article of manufacture or kit described above is itself a still further embodiment of the invention.
  • the invention provides methods for increasing the longevity of animals.
  • a method of the invention comprises administering to an old animal an antioxidant- comprising composition as more fully described herein.
  • the term "old” herein means relatively advanced in age, for example at least about one-third of a normal lifespan for the animal species.
  • an "old” animal is typically one of at least about 5 years of age.
  • the animal can be human or non-human.
  • the animal is a vertebrate, for example a fish, a bird, a reptile or a mammal.
  • the present method is especially useful for an animal having a normal life expectancy at birth of greater than about 1 year, for example greater than about 3 years, or greater than about 5 years.
  • the animal is non-murine, i.e., other than a rodent of the family Muridae.
  • the subject animal can be a member of the order Carnivora, including without limitation canine and feline species.
  • the animal is a companion animal.
  • a “companion animal” herein is an individual animal of any species kept by a human caregiver as a pet, or any individual animal of a variety of species that have been widely domesticated as pets, including dogs (Canis familiaris) and cats (Felis doniesticus), whether or not the individual animal is kept solely or partly for companionship.
  • “companion animals” herein include working dogs, farm cats kept for rodent control, etc., as well as pet dogs and cats.
  • the invention provides a method for increasing longevity of a canine animal such as a dog. The method comprises administering an antioxidant- comprising composition to the animal when the animal is old. In a particular embodiment, the canine is at least about 7 years old when the composition is administered.
  • the invention provides a method for increasing longevity of a feline animal such as a cat.
  • the method comprises administering an antioxidant-comprising composition to the animal when the animal is old.
  • the feline is at least about 7 years old when the composition is administered.
  • the animal receiving the antioxidant-comprising composition can optionally be at least about 8, for example at least about 9 or at least about 10, years old.
  • the canine or feline subject is a senior dog or cat, or a geriatric dog or cat, as these terms are generally used in literature pertaining to canine or feline nutrition.
  • the methods of the invention are suitable for other animals, including non-human mammals such as non-human primates (e.g., monkeys, chimpanzees, etc.), companion and working animals (e.g., horses, etc.), farm animals (e.g., goats, sheep, pigs, cattle, etc.), and wild and zoo animals (e.g., wolves, bears, deer, etc.).
  • non-human mammals such as non-human primates (e.g., monkeys, chimpanzees, etc.), companion and working animals (e.g., horses, etc.), farm animals (e.g., goats, sheep, pigs, cattle, etc.), and wild and zoo animals (e.g., wolves, bears, deer, etc.).
  • the methods of the invention also are generally suitable for use with non- mammalian animals, such as companion, farm, zoo, and wild birds, (including, for example, song birds, parrots, ducks, ge
  • the term "animal” means a human or non-human animal, including avian, bovine, canine, equine, feline, hicrine, murine, ovine, and porcine animals. Preferably, the animal is a canine or feline.
  • the methods of the invention comprise administering to an animal an antioxidant-comprising composition. The total antioxidant amount of the one or more antioxidants in the composition is sufficient, upon administration of the composition to an old animal, to increase the longevity of the animal.
  • the composition is administered at a frequency and for a period effective to increase longevity of the animal.
  • the phrase "a total antioxidant amount sufficient to increase the longevity of the animal" herein should be read in the context of a regimen of repeated administration at such a frequency and over such a period.
  • the composition is administered at least once daily, but in certain situations less frequent, e.g., twice weekly or weekly, administration can be effective.
  • administration should continue for a prolonged period, for example at least about 6 months, or at least about 1 year, or at least about 2 years, or at least about 3 years. In one embodiment, administration continues from a time of initiation for substantially the remainder of the animal's life.
  • the time of initiation is at any stage of the animal's life (i.e., there is no upper or lower age limit for initiating administration), so long as at least part of the administration regimen occurs when the animal is old. In a particular embodiment, however, administration is initiated when the animal is already old. For example, in the case of canine and feline companion animals, administration can be initiated when the animal is at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 years old.
  • a single antioxidant-comprising composition of the invention is administered to the animal for the entire period of administration, hi other embodiments, different antioxidant-comprising compositions are administered to the animal at different times.
  • the selection and/or amounts of individual antioxidants can, if desired, vary over the period of administration.
  • an antioxidant-comprising composition of the invention is formulated for oral administration.
  • a composition can be a food composition, a supplement, a treat or a toy, it being noted that some, but not all, supplements, treats and toys are themselves food compositions.
  • Food compositions are administered to the animal by feeding.
  • a food composition useful in the method of the invention is typically one that is nutritionally adapted for feeding to such an animal.
  • a food composition so adapted is referred to herein as a "pet food”.
  • Pet foods can be more particularly adapted to the special nutritional needs of canines or felines, or to certain subpopulations thereof such as large-breed dogs, adult dogs or cats, senior dogs or cats, geriatric dogs or cats, etc.
  • an antioxidant-comprising food composition provides a substantially nutritionally complete diet for the animal.
  • a "nutritionally complete diet” is a diet that includes sufficient nutrients for maintenance of normal health of a healthy animal on the diet.
  • an antioxidant-comprising food composition is a supplement, i.e., a food composition used with another food composition to improve the nutritive balance or performance of the diet as a whole.
  • Such supplements include compositions that are fed undiluted as a supplement to other foods, offered free choice with other parts of an animal's ration that are separately available to the animal, or diluted and mixed with an animal's regular food to produce a substantially nutritionally complete diet.
  • Supplements can alternatively be in a form other than a food composition, for example in a pharmaceutical-like dosage form including, for example, powders, liquids, syrups, pills, etc.
  • an antioxidant-comprising food composition is a treat.
  • Treats include, for example, compositions given to an animal as a reward or to entice the animal to eat during a non-meal time.
  • Treats for dogs that are food compositions having at least some nutritional value include, for example, dog biscuits. Treats can alternatively be substantially non-nutritional (except to the extent that the one or more antioxidants therein can be considered nutrients).
  • An antioxidant-comprising composition useful herein can itself form a treat, be coated onto an existing treat, or both.
  • an antioxidant-comprising composition is a toy adapted for oral use by an animal.
  • Toys include, for example, chewable toys, such as artificial bones for dogs.
  • a composition useful herein can form a coating on the surface of a toy or on the surface of a component of a toy, be incorporated partially or fully throughout the toy, or both.
  • suitable toys including partially consumable toys (e.g., toys comprising plastic components) and fully consumable toys (e.g., rawhides and various artificial bones).
  • Toys are available for human and non-human use, particularly for companion, farm, and zoo animal use, and more particularly for dog, cat, or bird use.
  • the antioxidant-comprising compositions useful herein are food compositions meeting the typical food intake requirements of the animal. Typical food intake requirements for old dogs and cats are shown in Table 1.
  • compositions useful herein comprise one or more antioxidants (i.e., materials that either directly quench a free radical or indirectly cause a free radical to be quenched).
  • materials that exhibit free radical quenching or absorbing capacity can be used in the antioxidant-comprising compositions of the invention (for example, fruits, vegetables, certain vitamins, and other chemical compounds).
  • Raw ingredients with high oxygen radical absorbing content include, for example, raw spinach pomace, raw tomato pomace, raw citrus pulp, raw grape pomace, raw carrot granules, raw broccoli, raw green tea, raw corn gluten meal, and raw rice bran.
  • Foods or food products that exhibit free radical quenching or absorbing capacity include, for example, spinach (e.g., spinach pomace), tomato (e.g., tomato pomace), citrus fruit (e.g., citrus pulp), grape (e.g., grape pomace), carrot (e.g., carrot granules), broccoli, corn gluten meal, and rice bran.
  • spinach e.g., spinach pomace
  • tomato e.g., tomato pomace
  • citrus fruit e.g., citrus pulp
  • grape e.g., grape pomace
  • carrot e.g., carrot granules
  • broccoli corn gluten meal
  • rice bran e.g., broccoli, corn gluten meal, and rice bran.
  • Compounds that exhibit free radical quenching or absorbing capacity include, for example, coenzyme Q 1 O (ubiquinone), beta-carotene, astaxanthin (3,3'-dihydroxy-4,4'-diketo-beta- carotene), glutathione, L-carnitine, alpha-lipoic acid, lutein, lycopene, N-acetylcysteine, polyphenols, S-adenosylmethionine, selenium, soy isoflavones, taurine, tocotrienols, vitamin C, and vitamin E.
  • a composition used in practice of the invention comprises vitamin E.
  • vitamin E herein means any form of vitamin E suitable for consumption by an animal including, but not limited to, any tocopherol or tocotrienol compound, any enantiomer or racemate thereof, and any mixture of such compounds having vitamin E activity, e.g., ⁇ -tocopherol (5,7,8-trimethyltocol), ⁇ -tocopherol (5,8- dimethyltocol), ⁇ -tocopherol (7,8-dimethyltocol), ⁇ -tocopherol (8-methyltocol), ⁇ -tocotrienol (5,7,8-trimethyltocotrienol), ⁇ -tocotrienol (5,8-dimethyltocotrienol), ⁇ -tocotrienol (7,8-dimethyltocotrienol), and ⁇ -tocotrienol (8-methyltocotrienol).
  • ⁇ -tocopherol 5,7,8-trimethyltocol
  • ⁇ -tocopherol 5,8- dimethyltocol
  • Vitamin E can be administered as any one or a mixture of the above compounds or in the form of various derivatives thereof such as esters, including vitamin E acetate, succinate, palmitate and the like, that exhibit vitamin E activity after ingestion by an animal.
  • vitamin E as used in the present method comprises ⁇ -tocopherol or an ester thereof.
  • Vitamin E amounts are expressed herein as DL- ⁇ -tocopheryl acetate equivalent amounts.
  • a composition can comprise from about 100 ppm to about 2,000 ppm, for example from about 150 ppm to about 1,500 ppm, or from about 500 ppm to about 1,000 ppm, vitamin E.
  • a composition used in practice of the invention comprises vitamin C.
  • vitamin C herein means any form of vitamin C suitable for consumption by an animal including, but not limited to, ascorbic acid, L-ascorbic acid, and various derivatives thereof such as calcium phosphate salt, cholesteryl salt, and ascorbate-2- monophosphate.
  • Salts of vitamin C include the sodium salt, calcium salt, zinc salt, and ferrous salt.
  • Esters include stearate, palmitate and like derivatives.
  • Vitamin C can be in any physical form such as a liquid, a semisolid, a solid, or a heat stable form that exhibits vitamin C activity after ingestion by an animal. Vitamin C amounts are expressed herein as ascorbic acid.
  • a composition can comprise from about 25 ppm to about 10,000 ppm, for example from about 50 ppm to about 5,000 ppm, or from about 75 ppm to about 1,000 ppm, vitamin C.
  • a composition used in practice of the invention comprises alpha-lipoic acid.
  • a composition can comprise from about 25 ppm to about 600 ppm, for example from about 50 ppm to about 200 ppm, or from about 100 ppm to about 200 ppm, alpha-lipoic acid.
  • Alpha-lipoic acid can be administered for example as an acid or lipoate derivative as described in U.S. Patent No. 5,621,117.
  • a composition used in practice of the invention comprises L-carnitine. Generally, compositions that are administered to cats comprise slightly higher L-carnitine amounts than the corresponding compositions for dogs.
  • compositions that are administered to cats can comprise from about 100 ppm to about 5,000 ppm, for example from about 200 ppm to about 600 ppm, or from about 400 ppm to about 600 ppm, L-carnitine.
  • compositions that are administered to dogs can comprise from about 50 ppm to about 5,000 ppm, for example from about 100 ppm to about 400 ppm, or from about 200 ppm to about 400 ppm, L-carnitine.
  • L-carnitine can be administered as L-carnitine or as a derivative, for example, a salt (for example, hydrochloride), ester (for example, fumarate ester or succinate ester), or acetylated L-carnitine.
  • An antioxidant-comprising composition can optionally comprise one or more of beta-carotene, for example in an amount from about 1 ppm to about 15 ppm; selenium, for example in an amount from about 0.1 ppm to about 5 ppm; lutein, for example in an amount from about 5 ppm to about 15 ppm; coenzyme Q 1O , for example in an amount from about 25 ppm to about 100 ppm; S-adenosylmethionine, for example in an amount from about 50 ppm to about 100 ppm; taurine, for example in an amount from about 500 ppm to about 1500 ppm; soy isoflavones, for example in an amount from about 25 ppm to about 200 ppm; N-acetylcysteine, for example in an amount from about 50 ppm to about 1600 ppm; glutathione, for example in an amount from about 50 ppm to about 250 ppm; and/or ginkgo
  • an antioxidant-comprising composition comprises more than one of the above-enumerated antioxidants.
  • such a composition comprises vitamin E, vitamin C, L-carnitine, and alpha-lipoic acid.
  • the composition of this embodiment comprises from about 50 ppm to about 10,000 ppm vitamin C, from about 100 ppm to about 2,000 ppm vitamin E, from about 25 ppm to about 600 ppm alpha-lipoic acid, and from about 100 ppm to about 5,000 ppm L-carnitine.
  • the composition of this embodiment comprises from about 50 ppm to about 100 ppm vitamin C, from about 500 ppm to about 1,000 ppm vitamin E, from about 100 ppm to about 200 ppm alpha-lipoic acid, and from about 200 ppm to about 400 ppm L-carnitine.
  • an antioxidant-comprising composition comprises vitamin E, vitamin C, L-carnitine, alpha-lipoic acid, beta-carotene, and taurine.
  • the composition of this embodiment comprises from about 50 ppm to about 10,000 ppm vitamin C, from about 100 ppm to about 2,000 ppm vitamin E, from about 25 ppm to about 600 ppm alpha-lipoic acid, from about 100 ppm to about 5,000 ppm L-carnitine, from about 1 ppm to about 25 ppm beta-carotene, and from about 500 ppm to about 8900 ppm taurine.
  • the composition of this embodiment comprises from about 50 ppm to about 100 ppm vitamin C, from about 500 ppm to about 1,000 ppm vitamin E, from about 100 ppm to about 200 ppm alpha-lipoic acid, from about 200 ppm to about 400 ppm, from about 5 ppm to about 15 ppm beta-carotene, and from about 1000 ppm to about 8900 ppm taurine.
  • a food composition is modified to replace some of the composition's ingredients having low oxygen radical absorbing capacity (for example, corn) with ingredients with high oxygen radical absorbing capacity.
  • a food composition can be formulated to replace from about 1% to about 5% of the ingredients having low oxygen radical absorbing capacity with one or more of spinach pomace, tomato pomace, citrus pulp, grape pomace, carrot granules, broccoli, green tea, ginkgo biloba, and corn gluten meal.
  • Food compositions useful herein can be prepared in, for example, a dry, canned, wet, or intermediate moisture form using conventional pet food manufacturing processes.
  • one or more antioxidants can be incorporated into the composition during processing, such as during and/or after mixing of other components of the composition. Distribution of the one or more antioxidants into the composition can be accomplished by conventional means.
  • ground animal and poultry proteinaceous tissues are mixed with other ingredients, including fish oils, cereal grains, other nutritionally balancing ingredients, special-purpose additives (e.g., vitamin and mineral mixtures, inorganic salts, cellulose and beet pulp, bulking agents, and the like); and water in an amount sufficient for processing is also added.
  • these ingredients can be mixed in a vessel suitable for heating while blending the components. Heating of the mixture may be affected in any suitable manner, such as, for example, by direct steam injection or by using a vessel fitted with a heat exchanger.
  • the mixture is heated to a temperature range of from about 50°F to about 212°F, for example from about 70°F to about 140°F. Temperatures outside these ranges are generally acceptable, but may be commercially impractical without use of other processing aids.
  • the material When heated to the appropriate temperature, the material will typically be in the form of a thick liquid. The thick liquid is filled into cans. A lid is applied, and the container is hermetically sealed. The sealed can is then placed into conventional equipment designed to sterilize the contents. This is usually accomplished by heating to temperatures of greater than about 23O 0 F for an appropriate time, which is dependent on, for example, the temperature used and the composition.
  • Food compositions can alternatively be prepared in a dry form using conventional processes.
  • dry ingredients including, for example, animal protein, plant protein, grains, etc.
  • Moist or liquid ingredients including fats, oils, animal protein, water, etc.
  • the mixture is then processed into kibbles or similar dry pieces. Kibble is often formed using an extrusion process in which the mixture of dry and wet ingredients is subjected to mechanical work at a high pressure and temperature, and forced through small openings and cut off into kibble by a rotating knife.
  • the wet kibble is then dried and optionally coated with one or more topical coatings which may include, for example, flavors, fats, oils, powders, and the like.
  • Kibble also can be made from the dough using a baking process, rather than extrusion, wherein the dough is placed into a mold before dry-heat processing.
  • Treats can be prepared by, for example, an extrusion or baking process similar to those described above for a dry food composition.
  • Other processes also may be used to either coat an antioxidant-comprising composition on the exterior of an existing treat form, or inject it into an existing treat form.
  • Toys useful herein can illustratively be prepared by coating an existing toy with an antioxidant-comprising composition.
  • an article of manufacture comprises a package containing an antioxidant-comprising composition as described herein. Any form of package appropriate to the nature of the composition can be used, including without limitation a can, jar, pouch, bag, bag in a box, and the like.
  • the article of this embodiment further comprises a means for communicating information about or instructions for administering the composition to an old animal to increase the longevity of the animal.
  • the communicating means is attached to or enclosed in the package.
  • a kit comprises a first package as described above containing an antioxidant-comprising composition, and a second package containing a food base.
  • the kit of this embodiment further comprises a means for communicating information about or instructions for adding the antioxidant-comprising composition to the food base, optionally with mixing.
  • the communicating means can specify amounts of the antioxidant-comprising composition to be added to a given amount of the food base as appropriate for particular situations.
  • the communicating means also provides information about or instructions for administering the resulting antioxidant- fortified food composition to an old animal to increase the longevity of the animal.
  • the communicating means can be provided together with or separately from the package, and can take any suitable form, such as those described above including one or more pages on a website.
  • Such a communicating means comprising for example a document such as a label, brochure, advertisement or package insert, a computer-readable digital or optical medium such as a diskette or CD, an audio presentation, for example on an audiotape or CD, a visual presentation, for example on a videotape or DVD, and/or one or more pages on a website, is itself a still further embodiment of the invention.
  • a group of twelve (12) aged beagles (average age 10.03 years) was initiated on a control food approximately the same as the one described in Table 1 above (the control food also contained approximately 100 ppm vitamin E).
  • a second group of twelve aged beagles (average age 10.16 years) was initiated on food A, which was similar to the control food but contained approximately 950 ppm vitamin E, approximately 300 ppm L-carnitine, approximately 100 ppm alpha-lipoic acid, and approximately 80 ppm vitamin C.
  • corn in an amount of approximately 5% of the control food was replaced in food A with approximately 1% tomato pomace, approximately 1% spinach, approximately 1% carrots, approximately 1% citrus pulp, and approximately 1% grape pomace.

Abstract

Cette invention concerne un procédé permettant d'allonger la durée de vie d'un vieil animal, lequel procédé consiste à administrer à l'animal une composition comprenant un ou plusieurs antioxydants en une quantité totale suffisante pour que la durée de vie de l'animal soit allongée.
EP06774663A 2005-07-14 2006-07-14 Procede permettant de prolonger la vie d'animaux Active EP1906912B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69914505P 2005-07-14 2005-07-14
PCT/US2006/027615 WO2007009111A1 (fr) 2005-07-14 2006-07-14 Procede permettant de prolonger la vie d'animaux

Publications (3)

Publication Number Publication Date
EP1906912A1 EP1906912A1 (fr) 2008-04-09
EP1906912A4 true EP1906912A4 (fr) 2009-06-03
EP1906912B1 EP1906912B1 (fr) 2012-08-15

Family

ID=37637503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06774663A Active EP1906912B1 (fr) 2005-07-14 2006-07-14 Procede permettant de prolonger la vie d'animaux

Country Status (12)

Country Link
US (2) US8722112B2 (fr)
EP (1) EP1906912B1 (fr)
JP (1) JP5284087B2 (fr)
CN (1) CN101262780B (fr)
AU (1) AU2006267068B2 (fr)
BR (1) BRPI0613000A2 (fr)
CA (1) CA2615060C (fr)
DK (1) DK1906912T3 (fr)
ES (1) ES2392738T3 (fr)
RU (1) RU2402919C2 (fr)
WO (1) WO2007009111A1 (fr)
ZA (1) ZA200800371B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US20090156658A1 (en) * 2000-10-31 2009-06-18 Hill's Pet Nutrition, Inc. Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals
US7666459B2 (en) 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
CN101107012A (zh) * 2004-11-24 2008-01-16 希尔氏宠物营养品公司 改进动物异生素物质肝清除率的方法
JP2008525528A (ja) 2004-12-29 2008-07-17 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における学習および／または記憶の衰退を抑制するための方法
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
JP4903796B2 (ja) * 2005-08-17 2012-03-28 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 腎疾患の予防及び治療のための方法及び組成物
MX2009008166A (es) 2007-02-01 2009-08-12 Iams Company Metodo para disminuir la inflamacion y estres en un mamifero usando antimetabolitos de glucosa, aguacate o extractos de aguacate.
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CA2746769C (fr) * 2008-12-16 2014-04-29 Hill's Pet Nutrition, Inc. Composition alimentaire contenant un anti-oxydant contribuant a ameliorer l'immunite antivirale des animaux de compagnie
EP2367549B1 (fr) 2008-12-30 2013-08-28 Hill's Pet Nutrition, Inc. Utilisation de l'acide alpha-lipoïque pour le traitement et la prévention de pathologies articulaires dégénératives, de l'ostéoarthrite, d'une lésion cartilagineuse, et de troubles apparentés chez les animaux de compagnie
CA2750137C (fr) * 2008-12-30 2014-09-23 Hill's Pet Nutrition, Inc. Compositions et procedes de traitement et de prevention de troubles lies au poids chez des animaux de compagnie
AU2010273505B2 (en) * 2009-07-14 2013-07-25 Hill's Pet Nutrition, Inc. Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102058026B (zh) * 2009-11-13 2013-04-10 福建格林生物科技有限公司 耐贮存二元软质水产饲料的生产及使用方法
MX340938B (es) * 2010-01-06 2016-08-01 Nestec Sa Regimenes dieteticos utiles para imitar la restriccion calorica.
JP2012060907A (ja) * 2010-09-15 2012-03-29 Kinki Univ ペットフード
CN103997904A (zh) * 2011-12-13 2014-08-20 希尔氏宠物营养品公司 治疗牙病症的组合物和方法
BR112015013683A2 (pt) * 2012-12-14 2017-07-11 Hills Pet Nutrition Inc alimentos anti-envelhecimento para animais de companhia
US10052282B2 (en) * 2016-09-23 2018-08-21 Sydney Baskins Pet hydration system
US20200163854A1 (en) * 2017-08-02 2020-05-28 Kyoto University Life-extending agent, anti-aging agent, cosmetic, and food/beverage composition
GB201914385D0 (en) * 2019-10-04 2019-11-20 Mars Inc Microbiome Interventions
CN111990574A (zh) * 2020-09-18 2020-11-27 内蒙古精晶生物科技有限公司 一种左旋肉碱营养泡腾片

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035943A2 (fr) * 2000-10-31 2002-05-10 Colgate-Palmolive Company Composition et methode
US20030035821A1 (en) * 2001-08-03 2003-02-20 Mars, Incorporated Antioxidant components for reduction of nucleic acid damage in companion animals
US20040047896A1 (en) * 2001-03-09 2004-03-11 Armand Malnoe Composition for improving age-related physiological deficits and increasing longevity
WO2005006877A1 (fr) * 2003-07-03 2005-01-27 Hill's Pet Nutrition, Inc. Compositions et procedes permettant de diminuer la deterioration liee a l'age des activites mentales des animaux de compagnie

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US519283A (en) * 1894-05-01 Electric arc lamp
US4006266A (en) * 1975-10-08 1977-02-01 The Quaker Oats Company Process for making a dry pet food having a hard component and a soft component
US4247562A (en) * 1978-12-21 1981-01-27 The Quaker Oats Company Moist pet food with blood chunks and a fluid gravy system
US5006361A (en) * 1980-10-03 1991-04-09 Cox James P Lipid pelletization methods, apparatus and products
US5030458A (en) * 1989-11-27 1991-07-09 Shug Austin L Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
US4883672A (en) * 1988-04-29 1989-11-28 Shug Austin L Method for preventing diet induced carnitine deficiency in domesticated dogs and cats
IE904034A1 (en) 1989-11-09 1991-05-22 Asta Medica Ag A medicament containing r-ó-lipoic acid or s-ó-lipoic acid¹as active substance
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
RU2038805C1 (ru) * 1993-02-10 1995-07-09 Всероссийский научно-исследовательский институт мясной промышленности Способ производства корма для собак и зверей
RU2071319C1 (ru) 1993-08-31 1997-01-10 Акционерное общество закрытого типа "Химбио" Способ улучшения процессов памяти
US5339771A (en) * 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US5894029A (en) * 1994-03-21 1999-04-13 Purebred Pet Products, Inc. Method of making pet snack food
DE4427079C2 (de) * 1994-07-30 2002-12-19 Viatris Gmbh Verfahren zur Racemisierung von Enantiomeren der alpha-Liponsäure
US5599835A (en) * 1994-11-23 1997-02-04 Fischer; Frederick B. Use of DL-lipoic acid as a medical food in the treatment of diabetes mellitus
RU2099078C1 (ru) 1994-12-08 1997-12-20 Акционерное общество закрытого типа "КОМКОН" Средство, обладающее антистрессовым, стресспротекторным, ноотропным, антиалкогольным и антинаркотическим действием, способы профилактики и лечения с его использованием
US5730988A (en) * 1995-04-20 1998-03-24 Lynntech, Inc. Nutritional supplements for improving glucose metabolism
DE19630350C2 (de) 1996-07-26 1998-08-20 Siemens Ag Ultraschallwandler
JPH1042798A (ja) * 1996-08-07 1998-02-17 Kagome Co Ltd リコピン含有飼料、並びにリコピン含有の畜肉または 卵
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
CA2269806C (fr) * 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Inclusion et encapsulation de particules a liberation controlee
US5937790A (en) * 1996-12-18 1999-08-17 Showa Denko Kabushiki Kaisha Anti-stress agent for animals and a method of reducing stress in animals
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
NZ338026A (en) 1997-03-27 2001-09-28 Michael J Sole Nutritional composition comprising L-carnitine, ubiquione and taurine and use for treating organ systems
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
US6232346B1 (en) * 1997-03-27 2001-05-15 Michael J. Sole Composition for improvement of cellular nutrition and mitochondrial energetics
US5851573A (en) * 1997-04-29 1998-12-22 The Iams Company Pet food composition for large breed puppies and method for promoting proper skeletal growth
US6346280B1 (en) 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
US5883083A (en) * 1997-06-09 1999-03-16 Harlmen, Inc. Dietary supplement for alleviating behavioral problems in canines and reducing seizures in canines and felines
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
DE19726519A1 (de) * 1997-06-23 1998-12-24 Asta Medica Ag Verfahren zur Herstellung trockener Thioctsäure
US6117477A (en) * 1998-03-18 2000-09-12 Kal Kan Foods, Inc. Multicomponent food product and methods of making and using the same
DE19818563C2 (de) 1998-04-25 2003-04-17 Sueddeutsche Kalkstickstoff Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
IT1299191B1 (it) 1998-06-23 2000-02-29 Sigma Tau Healthscience Spa Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
ID28460A (id) 1998-07-08 2001-05-24 Lipogenics Inc Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
ATE229277T1 (de) 1998-10-16 2002-12-15 Nestle Sa Proteinmaterial mit verlangsamtem verdaungsablauf und deren verwendung
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
NZ527924A (en) 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
US6284786B1 (en) 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
US6238708B1 (en) 1999-02-23 2001-05-29 The Iams Company Composition and process for controlling glucose metabolism in companion animals by dietary starch
US6365211B1 (en) * 1999-06-18 2002-04-02 The Procter & Gamble Co. Cooking aid with reduced foaming
CA2383715C (fr) 1999-09-09 2007-11-13 Societe Des Produits Nestle S.A. Procede visant a ameliorer l'etat d'animaux de compagnie ages
WO2001021208A1 (fr) 1999-09-23 2001-03-29 Juvenon Corporation Supplement nutritionnel fournissant une energie et une endurance accrues
CA2285490C (fr) 1999-10-07 2003-11-18 Michael J. Sole Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
NZ518739A (en) * 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
WO2001032168A1 (fr) 1999-11-03 2001-05-10 Juvenon, Inc. Traitement de la perte de memoire benigne
JP2001128637A (ja) * 1999-11-08 2001-05-15 Marugen Inryo Industry Co Ltd 微細柑橘パルプの製法及び微細柑橘パルプ利用の食品
US6379727B1 (en) * 1999-12-29 2002-04-30 John F. Addy Flavoring system for pet foods
ATE290400T1 (de) 2000-01-20 2005-03-15 Innovet Italia Srl Zusammensetzung zur behandlung von degenerativen gelenkerkrankungen
WO2001058271A1 (fr) 2000-01-25 2001-08-16 Juvenon, Inc. Supplements nutritionnels pour animaux de compagnie ages
US20030060503A1 (en) 2000-01-25 2003-03-27 Juvenon, Inc. Nutritional supplements for mature pets
EP1255454A2 (fr) * 2000-02-01 2002-11-13 Muscletech Research and Development Inc. Complement alimentaire a base d'acide alpha-lipoique destine a la masse maigre et a la resistance musculaire
US6669975B1 (en) * 2000-02-03 2003-12-30 Mars Incorporated Customized dietary health maintenance system for pets
PL357822A1 (en) 2000-04-14 2004-07-26 Mars Incorporated Compositions and methods for improving vascular health
US20020115710A1 (en) * 2000-10-31 2002-08-22 Zicker Steven Curtis Composition and method
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
EP1247456A3 (fr) 2001-02-28 2003-12-10 Pfizer Products Inc. Compositions pharmaceutiques savoureux pour les animaux domestiques
JP2003052338A (ja) * 2001-08-09 2003-02-25 Unitika Ltd 機能性卵及び養鶏用飼料
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
JP2003261456A (ja) 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
US6733793B2 (en) * 2002-06-04 2004-05-11 Metaproteomics, Llc Oral composition with insulin-like activities and methods of use
US8841344B2 (en) * 2002-10-03 2014-09-23 Hill's Pet Nutrition, Inc. Method of using omega-3 fatty acids
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US7078064B2 (en) * 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
JP4933097B2 (ja) * 2003-12-19 2012-05-16 株式会社メニコン 糖尿病および糖尿病合併症の治療・改善方法
ES2458308T5 (es) * 2004-09-21 2020-08-18 Société des Produits Nestlé SA Control de peso mejorado en animales de compañía de avanzada edad
US7544632B2 (en) * 2004-09-22 2009-06-09 Exxonmobil Research And Engineering Company Bulk Ni-Mo-W catalysts made from precursors containing an organic agent
CN101107012A (zh) 2004-11-24 2008-01-16 希尔氏宠物营养品公司 改进动物异生素物质肝清除率的方法
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP2006219467A (ja) 2005-02-10 2006-08-24 Oriza Yuka Kk 脂肪蓄積阻害剤
JP2007062332A (ja) 2005-09-02 2007-03-15 Toyo Mach & Metal Co Ltd 射出成形機
JP4765491B2 (ja) 2005-09-02 2011-09-07 リコープリンティングシステムズ株式会社 インクジェット式記録ヘッドの駆動方法及びインクジェット式記録ヘッド並びに画像記録装置
JP5119509B2 (ja) 2006-05-18 2013-01-16 ビーエイチエヌ株式会社 活動意欲向上剤
JP2008063234A (ja) 2006-09-04 2008-03-21 Pharma Foods International Co Ltd 慢性腎不全予防・改善組成物
US7282225B1 (en) * 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
JP5157007B2 (ja) 2007-05-11 2013-03-06 ビーエイチエヌ株式会社 骨強化剤
CA2691691C (fr) * 2007-06-20 2013-09-24 Seth J. Baum Compositions et procedes pour traiter la maladie chronique des reins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035943A2 (fr) * 2000-10-31 2002-05-10 Colgate-Palmolive Company Composition et methode
US20040047896A1 (en) * 2001-03-09 2004-03-11 Armand Malnoe Composition for improving age-related physiological deficits and increasing longevity
US20030035821A1 (en) * 2001-08-03 2003-02-20 Mars, Incorporated Antioxidant components for reduction of nucleic acid damage in companion animals
WO2005006877A1 (fr) * 2003-07-03 2005-01-27 Hill's Pet Nutrition, Inc. Compositions et procedes permettant de diminuer la deterioration liee a l'age des activites mentales des animaux de compagnie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HEAD E ET AL: "A LONGITUDINAL DIETARY ANTIOXIDANT INTERVENTION IN AGED CANINES IMPROVES LEARNING AND REDUCES PERIPHERAL MEASURES OF OXIDATIVE DAMAGE", 1 January 1900, BIOSIS,, XP002461957 *
IKEDA-DOUGLASS C J ET AL: "Prior Experience, Antioxidants, and Mitochondrial Cofactors Improve Cognitive Function in Aged Beagles", 1 January 2004, VETERINARY THERAPEUTICS, VETERINARY LEARNING SYSTEMS, TRENTON, NJ, US, PAGE(S) 5 - 16, ISSN: 1528-3593, XP008092011 *
SAVITHA S ET AL: "Oxidative stress on mitochondrial antioxidant defense system in the aging process: Role of dl-alpha-lipoic acid and l-carnitine", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 355, no. 1-2, 1 May 2005 (2005-05-01), pages 173 - 180, XP004835640, ISSN: 0009-8981 *
See also references of WO2007009111A1 *
SIWAK C T ET AL: "Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 29, no. 3, 1 March 2005 (2005-03-01), pages 461 - 469, XP004809116, ISSN: 0278-5846 *

Also Published As

Publication number Publication date
CN101262780A (zh) 2008-09-10
US8722112B2 (en) 2014-05-13
EP1906912A1 (fr) 2008-04-09
RU2402919C2 (ru) 2010-11-10
US20090155393A1 (en) 2009-06-18
WO2007009111A1 (fr) 2007-01-18
US20140205689A1 (en) 2014-07-24
BRPI0613000A2 (pt) 2012-12-04
ZA200800371B (en) 2013-03-27
CN101262780B (zh) 2013-04-24
ES2392738T3 (es) 2012-12-13
EP1906912B1 (fr) 2012-08-15
CA2615060C (fr) 2016-06-21
AU2006267068B2 (en) 2011-01-06
CA2615060A1 (fr) 2007-01-18
AU2006267068A1 (en) 2007-01-18
RU2008105553A (ru) 2009-08-20
JP5284087B2 (ja) 2013-09-11
JP2009501527A (ja) 2009-01-22
DK1906912T3 (da) 2012-12-03

Similar Documents

Publication Publication Date Title
US8722112B2 (en) Method for prolonging the life of animals
US8535708B2 (en) Methods for inhibiting a decline in learning and/or memory in animals
CA2784197C (fr) Methodes permettant d'ameliorer la qualite de vie d'un animal age
US8668922B2 (en) Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
EP2007368A2 (fr) Compositions et procedes visant a accroitre le statut antioxydant des animals
RU2482694C2 (ru) Композиции и способы лечения и профилактики нарушений, связанных с лишним весом у животных-компаньонов
CA2750140C (fr) Utilisation de l'acide lipoique pour le traitement et la prevention de pathologies articulaires degeneratives, de l'osteoarthrite, d'une lesion cartilagineuse, et de troubles apparentes chez les animaux de compagnie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/87 20060101ALI20080516BHEP

Ipc: A61K 36/81 20060101ALI20080516BHEP

Ipc: A23K 1/00 20060101AFI20080516BHEP

Ipc: A61K 36/752 20060101ALI20080516BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/81 20060101ALI20090427BHEP

Ipc: A23K 1/00 20060101AFI20080516BHEP

Ipc: A61K 31/385 20060101ALI20090427BHEP

Ipc: A61K 31/375 20060101ALI20090427BHEP

Ipc: A61K 36/87 20060101ALI20090427BHEP

Ipc: A61K 31/355 20060101ALI20090427BHEP

Ipc: A61K 31/205 20060101ALI20090427BHEP

Ipc: A23K 1/16 20060101ALI20090427BHEP

Ipc: A61K 36/752 20060101ALI20090427BHEP

17Q First examination report despatched

Effective date: 20100730

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006031461

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0006000000

Ipc: A23K0001180000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A23K 1/16 20060101ALI20120112BHEP

Ipc: A23K 1/18 20060101AFI20120112BHEP

Ipc: A61K 36/21 20060101ALI20120112BHEP

Ipc: A61K 45/06 20060101ALI20120112BHEP

Ipc: A61K 8/44 20060101ALI20120112BHEP

Ipc: A61K 8/67 20060101ALI20120112BHEP

Ipc: A61K 36/23 20060101ALI20120112BHEP

Ipc: A61K 31/205 20060101ALI20120112BHEP

Ipc: A61K 31/385 20060101ALI20120112BHEP

Ipc: A61K 31/355 20060101ALI20120112BHEP

Ipc: A61K 31/375 20060101ALI20120112BHEP

Ipc: A61K 36/752 20060101ALI20120112BHEP

Ipc: A61K 8/97 20060101ALI20120112BHEP

Ipc: A61K 36/81 20060101ALI20120112BHEP

Ipc: A61Q 19/08 20060101ALI20120112BHEP

Ipc: A61K 36/87 20060101ALI20120112BHEP

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

Ref country code: AT

Ref legal event code: REF

Ref document number: 570333

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006031461

Country of ref document: DE

Effective date: 20121018

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2392738

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20121213

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 570333

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121217

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121116

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006031461

Country of ref document: DE

Effective date: 20130516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060714

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130714

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20160726

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160722

Year of fee payment: 11

Ref country code: DK

Payment date: 20160725

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20160726

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006031461

Country of ref document: DE

Representative=s name: WUESTHOFF & WUESTHOFF, PATENTANWAELTE PARTG MB, DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20170731

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20170801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170801

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170714

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170715

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190725

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190729

Year of fee payment: 14

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200731

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200714

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230727

Year of fee payment: 18